Physician profile
Michael Graves
NPI 1447871140
$1,540.40
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.82 · 2021: $208 · 2022: $396 · 2023: $185 · 2024: $548 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.11 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $200.58 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $188.03 | 2024-2025 | Airsupra |
| Horizon Therapeutics Plc | $180.97 | 2021-2022 | |
| Novo Nordisk INC | $131.39 | 2021-2024 | Wegovy |
| Astellas Pharma US INC | $124.85 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $122.55 | 2023 | Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.07 | 2020-2023 | Xifaxan, Trulance |
| Amgen INC. | $94.31 | 2024 | Krystexxa |
| Dexcom, INC. | $27.84 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.15 | 2022 | |
| Pfizer INC. | $18.37 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.85 | 2021 | |
| Currax Pharmaceuticals LLC | $14.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.